PMID- 30254819
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 10
IP  - 7
DP  - 2018 Jul 23
TI  - Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients.
PG  - e3030
LID - 10.7759/cureus.3030 [doi]
LID - e3030
AB  - Type 2 diabetes mellitus (T2DM) has high morbidity and results in increased risk 
      of mortality mainly due to cardiovascular diseases. Different factors have been 
      found to be responsible for the increased prevalence of coronary artery disease 
      (CAD) in T2DM. One of these factors includes raised serum levels of 
      lipoprotein(a) (Lp(a)). The present study was designed to evaluate the 
      association of Lp(a) levels with T2DM in Libyan patients and find the degree of 
      association between Lp(a), glycemic control, insulin, and lipid profile. The 
      study included 100 T2DM patients, recruited from the Benghazi Center for 
      Diagnosis and Treatment of Diabetes, and 30 apparently healthy age and 
      sex-matched individuals, to serve as controls. All participants completed a 
      questionnaire to obtain clinical information and medical history. Blood samples 
      were collected and analyzed for Lp(a), fasting blood glucose (FBS), HbA1c, 
      insulin, total cholesterol (TC), triglycerides (TAG), low-density lipoprotein c 
      (LDL-c), and high-density lipoprotein c (HDL-c). The results from the comparison 
      between the control and experimental groups showed that Lp(a) was significantly 
      higher in diabetic patients. It showed the positive correlation with TC and 
      LDL-c. On the contrary, it showed no significant correlations with glycemic 
      control parameters nor insulin, TAG, HDL-c, body mass index (BMI), and blood 
      pressor (BP). Cardiovascular disease (CVD) risk in type 2 diabetic patients could 
      be dependent on risk factors other than LDL-c, which may not be an independent 
      risk factor for the development and progression of atherogenesis in T2DM. Lp(a) 
      may be a new metabolic syndrome risk factor, and it may be useful as a 
      cardiovascular risk biomarker in future clinical practice.
FAU - Peela, Jagannadha R
AU  - Peela JR
AD  - Genetics, St Matthew's University School of Medicine, Grand Cayman, CYM.
FAU - Latiwesh, Omar B
AU  - Latiwesh OB
AD  - Medical Laboratory, Higher Institute of Medical Professions, Benghazi, LBY.
FAU - Elshaari, Farag
AU  - Elshaari F
AD  - Biochemistry, Higher Institute of Medical Professions, Benghazi, LBY.
FAU - Hussain, Azhar
AU  - Hussain A
AD  - Medicine, Xavier University School of Medicine, Oranjestad, ABW.
FAU - Tabrez, Elsa
AU  - Tabrez E
AD  - Medicine, St. Matthew's University School of Medicine, George Town, CYM.
FAU - Viglianco, Emily
AU  - Viglianco E
AD  - Medicine, Xavier University School of Medicine, Oranjestad, ABW.
FAU - Edwards, Ajene
AU  - Edwards A
AD  - Medicine, Xavier University School of Medicine, Oranjestad, ABW.
FAU - Ali, Farwa
AU  - Ali F
AD  - Medicine, American University of Antigua College of Medicine, New York, USA.
FAU - Rawal, Avinash K
AU  - Rawal AK
AD  - Biochemistry, St. Matthew's University School of Medicine, Grand Cayman, CYM.
LA  - eng
PT  - Journal Article
DEP - 20180723
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC6150746
OTO - NOTNLM
OT  - cardiovascular disease
OT  - diabetic dyslipidemia
OT  - hyperglycemia
OT  - lipoprotein(a)
OT  - type 2 diabetes mellitus
COIS- The authors have declared that no competing interests exist.
EDAT- 2018/09/27 06:00
MHDA- 2018/09/27 06:01
PMCR- 2018/07/23
CRDT- 2018/09/27 06:00
PHST- 2018/09/27 06:00 [entrez]
PHST- 2018/09/27 06:00 [pubmed]
PHST- 2018/09/27 06:01 [medline]
PHST- 2018/07/23 00:00 [pmc-release]
AID - 10.7759/cureus.3030 [doi]
PST - epublish
SO  - Cureus. 2018 Jul 23;10(7):e3030. doi: 10.7759/cureus.3030.